A phase III, randomized, double-blind study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus dacarbazine in patients (pts) with previously untreated, unresectable, or metastatic melanoma (MEL).

被引：0
|
作者：
Robert, Caroline
Ascierto, Paolo Antonio
Maio, Michele
Hernberg, Micaela
Schmidt, Henrik
Waxman, Ian
Garbe, Claus
Lebbe, Celeste
Hauschild, Axel
机构：
[1] Inst Gustave Roussy, Villejuif, France
[2] Ist Nazl Tumori Fdn, Naples, Italy
[3] Univ Hosp Siena, Ist Toscana Tumori, Siena, Italy
[4] Univ Helsinki, Cent Hosp, Helsinki, Finland
[5] Aarhus Univ Hosp, DK-8000 Aarhus, Denmark
[6] Bristol Myers Squibb Co, Princeton, NJ USA
[7] Eberhard Karls Univ Tubingen, Tubingen, Germany
[8] Hop St Louis, Paris, France
[9] Univ Kiel, Kiel, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS9106
引用
收藏
页数：1
相关论文
共 50 条
  • [1] An exploratory study of the biologic effects of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) treatment in patients (pts) with advanced (unresectable or metastatic) melanoma (MEL)
    Sosman, Jeffrey Alan
    Martin-Algarra, Salvador
    Wolchok, Jedd D.
    Sharfman, William Howard
    Bhatia, Shailender
    Hodi, F. Stephen
    Hwu, Wen-Jen
    Gajewski, Thomas
    Slingluff, Craig L.
    Kaufman, Howard
    Gupta, Manish
    McGirr, Analia
    Horak, Christine E.
    Ahlers, Christoph Matthias
    Wigginton, Jon M.
    Urba, Walter John
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [2] Phase 2 study of nivolumab (Anti-PD-1; ONO-4538/BMS-936558) in patients with advanced melanoma
    Yamazaki, N.
    Tahara, H.
    Uhara, H.
    Moroi, Y.
    Kiyohara, Y.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S868 - S868
  • [3] Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL)
    Wolchok, Jedd D.
    Kluger, Harriet M.
    Callahan, Margaret K.
    Postow, Michael Andrew
    Gordon, Ruth Ann
    Segal, Neil Howard
    Rizvi, Naiyer A.
    Lesokhin, Alexander M.
    Reed, Kathleen
    Burke, Matthew M.
    Caldwell, Anne
    Kronenberg, Stephanie Anne
    Agunwamba, Blessing
    Feely, William
    Hong, Quan
    Horak, Christine E.
    Korman, Alan J.
    Wigginton, Jon M.
    Gupta, Ashok Kumar
    Sznol, Mario
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] An open-label, randomized, phase II study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) given sequentially with ipilimumab in patients (pts) with advanced or metastatic melanoma (MEL).
    Hodi, F. Stephen
    Baudelet, Christine
    Chen, Allen C.
    Weber, Jeffrey S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [5] Combined nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab in the treatment of advanced melanoma (MEL) patients (pts): Safety and clinical activity
    Sznol, M.
    Callahan, M. K.
    Kluger, H.
    Postow, M. A.
    Burke, M.
    Hong, Q.
    Selby, M.
    Korman, A.
    Gupta, A.
    Wolchok, J. D.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S866 - S866
  • [6] Phase 2 study of Nivolumab (Anti-PD-1; ONO-4538/BMS-936558) in Japanese patients with advanced melanoma: Preliminary report
    Yamazaki, N.
    Kiyohara, Y.
    Uhara, H.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S110 - S110
  • [7] Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).
    Amin, Asim
    Plimack, Elizabeth R.
    Infante, Jeffrey R.
    Ernstoff, Marc S.
    Rini, Brian I.
    McDermott, David F.
    Knox, Jennifer J.
    Pal, Sumanta Kumar
    Voss, Martin Henner
    Sharma, Padmanee
    Kollmannsberger, Christian K.
    Heng, Daniel Yick Chin
    Spratlin, Jennifer L.
    Shen, Yun
    Kurland, John F.
    Gagnier, Paul
    Hammers, Hans J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] Randomized phase IIb study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) alone or in combination with ipilimumab versus bevacizumab in patients (pts) with recurrent glioblastoma (GBM).
    Sampson, John Howard
    Viahovic, Gordana
    Desjardins, Annick
    Friedman, Henry S.
    Baehring, Joachim M.
    Hafler, David
    Rollin, Linda
    Coric, Viad
    Perez, Susan N.
    Reardon, David A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] A phase III comparative study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus everolimus in patients (pts) with advanced or metastatic renal cell carcinoma (mRCC) previously treated with antiangiogenic therapy.
    Motzer, Robert John
    Bono, Petri
    Hudes, Gary R.
    Tomita, Yoshihiko
    Ravaud, Alain
    Waxman, Ian
    Gore, Martin Eric
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients with metastatic renal cell carcinoma (mRCC)
    Amin, A.
    Plimack, E. R.
    Infante, J. R.
    Ernstoff, M. S.
    Rini, B.
    Mcdermott, D. F.
    Knox, J.
    Pal, S. K.
    Voss, M. H.
    Sharma, P.
    Kollmannsberger, C.
    Heng, D. Y. C.
    Spratlin, J.
    Shen, Y.
    Kurland, J. F.
    Gagnier, P.
    Hammers, H.
    [J]. BJU INTERNATIONAL, 2014, 114 : 2 - 2
12345